Aspire Biopharma shareholders approve reverse stock split and authorized share increase

Aspire Biopharma Holdings, Inc.

Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.
Authorized common stock increase from 490M to 700M shares passed: 1,925,368 for, 524,501 against, 7,403 abstain.
Series A Preferred issuance for conversion shares and floor price approved: 1,466,141 for, 203,756 against, 8,652 abstain, 1,012,844 broker non-votes.
ELOC Agreement share issuance approved: 1,469,985 for, 203,926 against, 4,638 abstain, 1,012,844 broker non-votes.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.